Lot-to-Lot Consistency in IVD Raw Materials
Updated 2026-09-28
Why a silent change between batches is the most expensive failure mode in assay development — and how to protect against it.
The hidden failure mode
Most assay failures caused by raw materials are not obvious contaminants; they are small differences in purity profile, glycosylation, activity or aggregate content between one batch and the next.
What to demand from a supplier
Per-lot CoA with the characterisation methods stated, retained samples from previous lots, advance notice of process changes, and a supplier willing to reserve a validated lot for your reorders.
Practical protection
Keep a reference aliquot of a qualified lot, re-test a small side-by-side on each new lot, and document the lot number in your experimental records so anomalies can be traced backwards.
What actually drifts between lots
Lot variation is rarely a dramatic failure, which is precisely why it is expensive. It looks like an aggregate species that was two per cent in the qualified lot and seven per cent in the new one. It looks like a glycosylation profile that shifts by one antenna and changes the binding of one of your two antibodies while the other is unaffected. It looks like an activity that falls by a fifth in a functional assay while the purity by SDS-PAGE is unchanged. Or it looks like an endotoxin figure drifting from 0.05 to 0.4 EU/µg — irrelevant in an ELISA, decisive the moment the protein is put onto living cells. None of these would fail an identity test. None would appear on a CoA as a deviation. They appear instead as a standard curve that needs re-fitting every few months, or as a result that a colleague cannot reproduce.
Making consistency a policy rather than a hope
Three habits carry most of the protection. Reserve a reference aliquot from a qualified lot and treat it as a control rather than as stock — it is the baseline against which every later lot is judged, and it cannot be recreated once it is gone. Run a small side-by-side whenever a new lot arrives, comparing the new material against that reference in the assay you actually use rather than trusting the headline purity on the CoA. And record the lot number in your experimental records, not only in the purchasing system: when someone revisits the data in two years, the lot number is the only link between a set of numbers and the material that produced them. On the supplier side, ask two direct questions — whether historical lots are retained, and whether you would be notified before a process change. Both are routine practice among manufacturers supplying regulated industries, and both are cheap for them to answer honestly.
References
These references concern the analytes and the analytical literature — not our materials. Each entry was checked against its PubMed record, and the PMID links to that record so you can verify the details yourself rather than taking our word for it.
- Rosano GL, Morales ES, Ceccarelli EA. New tools for recombinant protein production in Escherichia coli: A 5-year update. Protein Sci. 2019;28:1412-1422. PMID 31219641
- Findlay JW, Smith WC, Lee JW, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal. 2000;21:1249-73. PMID 10708409
Related materials
Human Recombinant Soluble ST2 (sST2 / IL1RL1) →Recombinant Cardiac Troponin I (cTnI) →Broad-Spectrum IVD Reagent Preservative →Request a Quote or Sample
Tell us your application, target purity and quantity — we reply within one business day.